Research map: Combination therapy in metabolic dysfunction-associated steatohepatitis

Back to the article

Papers in this map

  1. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis · Stephen A. Harrison · 2024 · 1982 citations · Cited by this paper
  2. Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial · 2026 · Related
  3. Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis · Arun J. Sanyal · 2025 · 985 citations · Cited by this paper
  4. Ethnicity, diversity, and inclusion in gastroenterology: from representation to system performance · 2026 · Related
  5. Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH · Rohit Seth Loomba · 2023 · 505 citations · Cited by this paper
  6. Cyclic exclusive enteral nutrition in paediatric Crohn's disease – Authors’ reply · 2026 · Related
  7. FGF21 agonists: An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond · Stephen A. Harrison · 2024 · 164 citations · Cited by this paper
  8. Rome V: refining the language of gut–brain disorders · 2026 · Related
  9. Efruxifermin in Compensated Liver Cirrhosis Caused by MASH · Mazen Noureddin · 2025 · 127 citations · Cited by this paper
  10. The spectrum of steatotic liver disease in the USA – Authors’ reply · 2026 · Related
  11. Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study · Stephen A. Harrison · 2024 · 99 citations · Cited by this paper
  12. Drugging the undruggable in pancreatic cancer · 2026 · Related
  13. Effects of Resmetirom on Metabolic‐Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon‐Like Peptide‐1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO ‐ NASH Trial · Mazen Noureddin · 2025 · 25 citations · Cited by this paper
  14. Pathophysiology of irritable bowel syndrome · 2026 · Related
  15. Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities · Xiao-Dong Zhou · 2025 · 22 citations · Cited by this paper
  16. Translating the gut microbiome: where are we? · 2026 · Related
  17. Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial · Rohit Loomba · 2026 · 3 citations · Cited by this paper
  18. Therapeutic drift or formulation drift: avoiding misconceptions about rifaximin and antimicrobial resistance in cirrhosis · 2026 · Related

Source: OpenAlex (CC0)